vs
Apellis Pharmaceuticals, Inc.（APLS）与VSE CORP（VSEC）财务数据对比。点击上方公司名可切换其他公司
VSE CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.5倍（$301.2M vs $199.9M），VSE CORP净利率更高（4.5% vs -29.5%，领先34.0%），VSE CORP同比增速更快（0.7% vs -5.9%），VSE CORP自由现金流更多（$30.9M vs $-14.3M），过去两年VSE CORP的营收复合增速更高（11.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
VSE Corporation是全球领先的后市场分销与维修服务供应商，依托两大核心业务板块助力客户提升高价值核心业务资产的运营效率与使用寿命。旗下航空板块为商用、公务及通用航空运营商提供售后零件配送、零部件与发动机附件的维护、维修及大修（MRO）服务，车队板块聚焦商用资产运维支持。
APLS vs VSEC — 直观对比
营收规模更大
VSEC
是对方的1.5倍
$199.9M
营收增速更快
VSEC
高出6.7%
-5.9%
净利率更高
VSEC
高出34.0%
-29.5%
自由现金流更多
VSEC
多$45.2M
$-14.3M
两年增速更快
VSEC
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $301.2M |
| 净利润 | $-59.0M | $13.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 10.8% |
| 净利率 | -29.5% | 4.5% |
| 营收同比 | -5.9% | 0.7% |
| 净利润同比 | -62.2% | 3.9% |
| 每股收益（稀释后） | $-0.40 | $0.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSVSEC
| Q4 25 | $199.9M | $301.2M | ||
| Q3 25 | $458.6M | $282.9M | ||
| Q2 25 | $178.5M | $272.1M | ||
| Q1 25 | $166.8M | $256.0M | ||
| Q4 24 | $212.5M | $299.0M | ||
| Q3 24 | $196.8M | $273.6M | ||
| Q2 24 | $199.7M | $266.0M | ||
| Q1 24 | $172.3M | $241.5M |
净利润APLSVSEC
| Q4 25 | $-59.0M | $13.6M | ||
| Q3 25 | $215.7M | $3.9M | ||
| Q2 25 | $-42.2M | $3.2M | ||
| Q1 25 | $-92.2M | $-9.0M | ||
| Q4 24 | $-36.4M | $13.1M | ||
| Q3 24 | $-57.4M | $11.7M | ||
| Q2 24 | $-37.7M | $-2.8M | ||
| Q1 24 | $-66.4M | $-6.6M |
营业利润率APLSVSEC
| Q4 25 | -25.6% | 10.8% | ||
| Q3 25 | 48.7% | 3.6% | ||
| Q2 25 | -18.6% | 8.3% | ||
| Q1 25 | -50.0% | 9.6% | ||
| Q4 24 | -12.3% | 9.2% | ||
| Q3 24 | -24.0% | 8.7% | ||
| Q2 24 | -14.7% | 2.3% | ||
| Q1 24 | -36.0% | 10.0% |
净利率APLSVSEC
| Q4 25 | -29.5% | 4.5% | ||
| Q3 25 | 47.0% | 1.4% | ||
| Q2 25 | -23.6% | 1.2% | ||
| Q1 25 | -55.3% | -3.5% | ||
| Q4 24 | -17.1% | 4.4% | ||
| Q3 24 | -29.2% | 4.3% | ||
| Q2 24 | -18.9% | -1.0% | ||
| Q1 24 | -38.5% | -2.7% |
每股收益（稀释后）APLSVSEC
| Q4 25 | $-0.40 | $0.64 | ||
| Q3 25 | $1.67 | $0.19 | ||
| Q2 25 | $-0.33 | $0.16 | ||
| Q1 25 | $-0.74 | $-0.44 | ||
| Q4 24 | $-0.30 | $0.79 | ||
| Q3 24 | $-0.46 | $0.63 | ||
| Q2 24 | $-0.30 | $-0.16 | ||
| Q1 24 | $-0.54 | $-0.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $69.4M |
| 总债务越低越好 | — | $292.8M |
| 股东权益账面价值 | $370.1M | $1.4B |
| 总资产 | $1.1B | $2.0B |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资APLSVSEC
| Q4 25 | $466.2M | $69.4M | ||
| Q3 25 | $479.2M | $8.8M | ||
| Q2 25 | $370.0M | $16.9M | ||
| Q1 25 | $358.4M | $5.7M | ||
| Q4 24 | $411.3M | $29.0M | ||
| Q3 24 | $396.9M | $7.9M | ||
| Q2 24 | $360.1M | $19.0M | ||
| Q1 24 | $325.9M | $10.6M |
总债务APLSVSEC
| Q4 25 | — | $292.8M | ||
| Q3 25 | — | $356.1M | ||
| Q2 25 | — | $379.2M | ||
| Q1 25 | — | $465.0M | ||
| Q4 24 | — | $430.2M | ||
| Q3 24 | — | $450.3M | ||
| Q2 24 | — | $463.5M | ||
| Q1 24 | $93.1M | $481.6M |
股东权益APLSVSEC
| Q4 25 | $370.1M | $1.4B | ||
| Q3 25 | $401.2M | $983.3M | ||
| Q2 25 | $156.3M | $979.5M | ||
| Q1 25 | $164.2M | $975.7M | ||
| Q4 24 | $228.5M | $988.2M | ||
| Q3 24 | $237.1M | $787.8M | ||
| Q2 24 | $264.3M | $781.3M | ||
| Q1 24 | $266.7M | $612.7M |
总资产APLSVSEC
| Q4 25 | $1.1B | $2.0B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $821.4M | $1.6B | ||
| Q1 25 | $807.3M | $1.7B | ||
| Q4 24 | $885.1M | $1.7B | ||
| Q3 24 | $901.9M | $1.5B | ||
| Q2 24 | $904.5M | $1.5B | ||
| Q1 24 | $831.9M | $1.3B |
负债/权益比APLSVSEC
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.39× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 0.44× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.59× | ||
| Q1 24 | 0.35× | 0.79× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $30.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 10.3% |
| 资本支出强度资本支出/营收 | 0.1% | 2.2% |
| 现金转化率经营现金流/净利润 | — | 2.77× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $5.7M |
8季度趋势，按日历期对齐
经营现金流APLSVSEC
| Q4 25 | $-14.2M | $37.6M | ||
| Q3 25 | $108.5M | $24.1M | ||
| Q2 25 | $4.4M | $11.9M | ||
| Q1 25 | $-53.4M | $-46.6M | ||
| Q4 24 | $19.4M | $55.4M | ||
| Q3 24 | $34.1M | $10.2M | ||
| Q2 24 | $-8.3M | $-17.5M | ||
| Q1 24 | $-133.0M | $-79.1M |
自由现金流APLSVSEC
| Q4 25 | $-14.3M | $30.9M | ||
| Q3 25 | $108.3M | $18.0M | ||
| Q2 25 | $4.4M | $6.3M | ||
| Q1 25 | $-53.4M | $-49.5M | ||
| Q4 24 | $19.3M | $52.1M | ||
| Q3 24 | — | $4.4M | ||
| Q2 24 | $-8.4M | $-21.5M | ||
| Q1 24 | $-133.3M | $-86.8M |
自由现金流率APLSVSEC
| Q4 25 | -7.1% | 10.3% | ||
| Q3 25 | 23.6% | 6.4% | ||
| Q2 25 | 2.5% | 2.3% | ||
| Q1 25 | -32.0% | -19.3% | ||
| Q4 24 | 9.1% | 17.4% | ||
| Q3 24 | — | 1.6% | ||
| Q2 24 | -4.2% | -8.1% | ||
| Q1 24 | -77.3% | -35.9% |
资本支出强度APLSVSEC
| Q4 25 | 0.1% | 2.2% | ||
| Q3 25 | 0.0% | 2.1% | ||
| Q2 25 | 0.0% | 2.1% | ||
| Q1 25 | 0.0% | 1.1% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.0% | 2.1% | ||
| Q2 24 | 0.0% | 1.5% | ||
| Q1 24 | 0.2% | 3.2% |
现金转化率APLSVSEC
| Q4 25 | — | 2.77× | ||
| Q3 25 | 0.50× | 6.16× | ||
| Q2 25 | — | 3.72× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.24× | ||
| Q3 24 | — | 0.87× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
VSEC
暂无分部数据
